Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab

Inclusion Criteria:

• Signing informed consent; ECOG 0-2 points;

• Age over 18 years old, gender is not limited;

• Esophageal squamous cell carcinoma confirmed by pathology or clinically diagnosed byimaging;

• Recurrence of the tumor area after radical surgery or radical chemoradiotherapy;Regional progression of advanced esophageal squamous cell carcinoma after first-lineor second-line treatment;

• Clinical staging: regional recurrence (rT0-4N0-3M0-1a) or regional progression (cT0-4N0-3M0-1) (AJCC/UICC esophageal cancer staging (8th edition));

• Tumor lesions can be evaluated;

• Expected survival ≥3 months;

• Major organ function is normal, meeting the following criteria: (i) blood routineexamination A.HB ≥90g/L; b.ANC≥1.5×109/L; C. PLT ≥80×109/L; (ii) Biochemicalexamination: a. ALT/AST≤2.5ULN; b. TBIL≤1.5ULN; c. Plasma Cr≤1.5ULN or creatinineclearance (CCr)≥60ml/min;

• Women of childbearing age must have had a pregnancy within 7 days before startingtreatment and the result is negative;

• All enrolled patients should take adequate contraceptive measures throughout thetreatment period and 4 weeks after completion;

• no serious hematopoietic function, heart function, endocrine and immune functiondefects;

• No patients with grade 3 or above other serious medical diseases.

Exclusion Criteria:

• Under 18 years of age; ECOG is greater than 2;

• The diagnosis of esophageal cancer is not supported by pathological biopsy or imageexamination;

• Salvage surgery was performed after tumor recurrence;

• The patient has any active autoimmune disease (such as the following, but notlimited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; The patient hadvitiligo; Those with complete remission of asthma in childhood can be includedwithout any intervention in adulthood; Patients with asthma requiring medicalintervention with bronchodilators are not included);

• Patients who were taking immunosuppressants or systemic hormone therapy forimmunosuppressive purposes (doses >10mg/ day of prednisone or other therapeutichormones) and continued to use within 2 weeks before enrollment;

• Patients with severe and/or uncontrolled concomitant disease of grade 3 or higher,including: poor blood pressure control, myocardial ischemia or myocardialinfarction, arrhythmia, active or uncontrolled severe infection; Liver diseases suchas decompensated liver disease, active hepatitis B (HBV-DNA≥104 copy numbers /ml or 2000IU/ml), or hepatitis C (hepatitis C antibody positive and HCV-RNA above thelower detection limit of analytical methods);

• Pregnant or lactating women;

• Patients who have a history of psychotropic drug abuse and cannot quit or havemental disorders;

• Patients who have participated in clinical trials of other drugs within four weeks; .Patients or family members refused to participate in the study.